1. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, Mcdermott DF, Knox JJ, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DY, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Hammers HH (2014) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s.
2. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17: 4232–4244.
3. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372: 311–319.
4. Armand P, Ansell SM, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, Timmerman J, Borrello I, Gutierrez M, Scott EC, Cattry D, Chapuy B, Ligon AH, Rodig SJ, Zhu L, Grosso JF, Kim SY, Shipp MA (2014) Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract]. Am Soc Hematol (Meeting Abstracts) 289.
5. Atkins MB, Kudchadkar RR, Sznol M, Mcdermott MD, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, Slingluff CL, Ernstoff MS, Fay JW, Friedlander PA, Gajewski T, Zarour HM, Rotem-Yehudar R, Sosman JA (2014) Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma [abstract]. J Clin Oncol (Meeting Abstracts) 32: 5s.